BridgeBio CEO Neil Kumar disposes of common shares worth $5.48 million

BridgeBio Pharma

BridgeBio Pharma

BBIO

0.00
  • BridgeBio Pharma CEO Neil Kumar disclosed sales of 80,000 common shares on May 7-8.
  • Sales were executed through Kumar Haldea Family Irrevocable Trust and Kumar Haldea Revocable Trust.
  • Weighted average sale prices ranged from $66.65 to $69.09.
  • Holdings following transactions: 234,451 shares held directly; 555,686 shares held via family irrevocable trust; 4,358,447 shares held via revocable trust.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001470831-26-000423), on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.